Search Results

Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, announced a Series C Financing close in excess of $30M. U.S. Venture Partners, led the round.

Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee RECOIL study.

Data Presented at the AVA Annual Scientific Meeting Shows Significantly Lower Complication and Failure Rates with Access Vascular’s HydroMID® Midline Catheter

Cagent Vascular, the exclusive developer of Serration Angioplasty (Serranator®), announced the results of a comparative sub-analysis of the PRELUDE-Below-the-Knee (BTK) study versus Plain Old Balloon Angioplasty (POBA).

enVVeno Medical Corporation (NASFAQ:NVNO) (“enVVeno” or the “Company”) today announced that positive interim venous ulcer healing data showing significant clinical improvement from the SAVVE U.S. pivotal trial for the VenoValve will be presented today at the Society for Vascular Surgery 2024 Vascular Annual Meeting in Chicago.

Cagent Vascular Inc., a developer of next generation angioplasty balloons using serration technology, announced the expansion of its product offering to include larger balloons to treat superficial femoral and popliteal arteries in the Above-the-Knee (ATK) segment.

enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting (VAM2024) being held June 18-22, 2024 in Chicago, IL.

Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, has announced the online publication of the one-year results of the DETOUR2 Trial in the Journal of Vascular Surgery.

Access Vascular, Inc. announced findings from new data showing a reduction in bacterial adhesion and thrombus accumulation in peripherally inserted central catheters and midline catheters with AVI’s MIMIX® hydrophilic biomaterial compared with conventional catheters.